According to a media release issued on March 18 by EDAP TMS, the US healthcare insurance firm CIGNA has agreed to cover the use of high-intensity focal ultrasound (HIFU) as a second-line, salvage therapy for men with radiorecurrent prostate cancer. Specifically, to quote the media release from EDAP TMS: The CIGNA policy aligns with National […]
↧
